Ascorbic acid as an adjunct therapy for anemia in erythropoietin-treated hemodialysis patients: a systematic review and meta-analysis
Clinical Kidney Journal · 01.06.2026 · 19 (6)
DOI: 10.1093/ckj/sfag070 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Kidney Journal, online erschienen am 22.04.2026. Verfasst von Salma Alejandra Beltrán Covarrubias und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Universidad de Guadalajara, Guadalajara, Mexico. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Anemia is a common complication in chronic kidney disease (CKD), especially in hemodialysis patients, causing fatigue and reduced quality of life. Standard treatments involve iron and erythropoietin (EPO). Ascorbic acid (vitamin C) supports iron metabolism by converting ferric to ferrous iron and enhancing absorption and mobilization. This systematic review and meta-analysis evaluated the effectiveness of ascorbic acid in improving hematologic and iron parameters in adult anemic patients undergoing maintenance hemodialysis.
Methods
Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive search was performed in PubMed, EMBASE, Cochrane, Scopus, Web of Science, CINAHL and Google Scholar through May 2025. Only randomized controlled trials and crossover studies assessing ascorbic acid in adult anemic hemodialysis patients were included. The protocol was registered in the International Prospective Register of Systematic Review (PROSPERO) (CRD420251056337). Primary outcomes were hemoglobin (Hb), ferritin, serum iron, transferrin saturation (TSAT) and total iron-binding capacity (TIBC). Meta-analyses used DerSimonian-Laird random-effects models.
Results
Of 479 screened articles, 14 studies were included. Ascorbic acid supplementation was associated with a modest but significant increase in Hb [mean difference (MD) 0.94 g/dL; 95% confidence interval (CI) 0.57 to 1.31; P < .01; I² = 87.2%] and TSAT (MD 6.86%; 95% CI 1.93 to 11.78; P < .01; I² = 96.7%). Ferritin levels showed a slight but significant reduction (MD −65.00 ng/mL; 95% CI −117.20 to −12.80; P = .01; I² = 57.2%), along with a decrease in TIBC (MD −22.54 µg/dL; 95% CI −42.37 to −2.72; P = .03; I² = 76.1%). EPO requirements expressed as units/kg/week were significantly reduced (MD −21.29; 95% CI −27.73 to −14.84; P < .01; I² = 0.0%). No significant changes were observed in serum iron levels or EPO dosage expressed as IU/week.
Conclusion
Ascorbic acid supplementation may confer modest hematologic benefits in hemodialysis patients with improvements in Hb, TSAT and iron utilization, and a small reduction in weight-adjusted erythropoiesis-stimulating agent dose. However, the certainty of evidence is low, and long-term safety and patient-centered outcomes remain unestablished.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Universidad de Guadalajara, Guadalajara, Mexico.
- Faculty of Medicine, Universidad De Guayaquil, Guayaquil, Ecuador.
- Faculty of Medicine, Centro de Estudios Universitarios Xochicalco Campus Tijuana, Tijuana, Mexico.
- Faculty of Medicine, Universidad Autónoma de Santo Domingo, Santo Domingo, Dominican Republic.
- Faculty of Medicine, Universidad Autónoma de Nuevo León, Facultad de Medicina, Monterrey, Mexico.
- Faculty of Medicine, Universidad Autónoma de Sinaloa, Facultad de Medicina, Culiacán, Sinaloa, Mexico.
ORCID-Profile: Salma Alejandra Beltrán Covarrubias, Angelo Magallanes Bajana, Alejandro Chen Liang, Yeison Cruz Castillo, Montserrat Villa Sánchez, José Antonio García-Erce
Zitieren
APA
Beltrán Covarrubias, S. A., Magallanes Bajana, A., Chen Liang, A., Cruz Castillo, Y., Villa Sánchez, M., De la Rosa Valdez, E., Sámano Sánchez, M., Shambhavi, S., Abbagoni, V., Pena Zapata, O. Y., Sanchez Cruz, C., García-Erce, J. A., & Calderón-Martínez, E. (2026). Ascorbic acid as an adjunct therapy for anemia in erythropoietin-treated hemodialysis patients: a systematic review and meta-analysis. Clinical Kidney Journal, 19(6). https://doi.org/10.1093/ckj/sfag070
Vancouver
Beltrán Covarrubias SA, Magallanes Bajana A, Chen Liang A, Cruz Castillo Y, Villa Sánchez M, De la Rosa Valdez E, et al. Ascorbic acid as an adjunct therapy for anemia in erythropoietin-treated hemodialysis patients: a systematic review and meta-analysis. Clinical Kidney Journal. 2026;19(6). doi:10.1093/ckj/sfag070
BibTeX
@article{BeltrnCovarrubias2026,
author = {Beltrán Covarrubias, Salma Alejandra and Magallanes Bajana, Angelo and Chen Liang, Alejandro and Cruz Castillo, Yeison and Villa Sánchez, Montserrat and De la Rosa Valdez, España and Sámano Sánchez, Michelle and Shambhavi, Shreya and Abbagoni, Vaidarshi and Pena Zapata, Oscar Yasser and Sanchez Cruz, Camila and García-Erce, José Antonio and Calderón-Martínez, Ernesto},
title = {Ascorbic acid as an adjunct therapy for anemia in erythropoietin-treated hemodialysis patients: a systematic review and meta-analysis},
journal = {Clinical Kidney Journal},
year = {2026},
volume = {19},
number = {6},
doi = {10.1093/ckj/sfag070}
}
EUVIMED